Sudeep Pharma Ltd
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
- Market Cap ₹ 9,201 Cr.
- Current Price ₹ 815
- High / Low ₹ 816 / 524
- Stock P/E 85.5
- Book Value ₹ 69.6
- Dividend Yield 0.00 %
- ROCE 20.7 %
- ROE 17.7 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.6%
- Debtor days have improved from 134 to 86.4 days.
Cons
- Stock is trading at 10.7 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 9.21% over past five years.
- Working capital days have increased from 168 days to 240 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 218 | 345 | 404 | 344 | 357 | 339 | |
| 172 | 277 | 315 | 211 | 224 | 219 | |
| Operating Profit | 46 | 68 | 89 | 133 | 133 | 120 |
| OPM % | 21% | 20% | 22% | 39% | 37% | 35% |
| 4 | 8 | 11 | 8 | 8 | 38 | |
| Interest | 1 | 2 | 5 | 4 | 6 | 6 |
| Depreciation | 4 | 4 | 5 | 5 | 6 | 7 |
| Profit before tax | 45 | 70 | 91 | 132 | 129 | 145 |
| Tax % | 22% | 26% | 26% | 26% | 26% | 26% |
| 35 | 52 | 67 | 98 | 96 | 108 | |
| EPS in Rs | 248.31 | 371.23 | 476.69 | 696.05 | 9.85 | 9.52 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | -6% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 17% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 24% |
| Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 10 | 11 |
| Reserves | 115 | 167 | 235 | 333 | 418 | 775 |
| 31 | 73 | 71 | 60 | 123 | 127 | |
| 67 | 92 | 109 | 56 | 54 | 61 | |
| Total Liabilities | 214 | 333 | 416 | 451 | 604 | 974 |
| 68 | 120 | 90 | 96 | 105 | 105 | |
| CWIP | 23 | 4 | 26 | 44 | 88 | 158 |
| Investments | 24 | 15 | 19 | 29 | 32 | 32 |
| 99 | 194 | 282 | 282 | 380 | 679 | |
| Total Assets | 214 | 333 | 416 | 451 | 604 | 974 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 36 | -5 | 42 | 59 | 59 | 96 | |
| -45 | -28 | -41 | -41 | -92 | -367 | |
| 13 | 40 | -10 | -16 | 54 | 242 | |
| Net Cash Flow | 4 | 7 | -9 | 2 | 22 | -28 |
| Free Cash Flow | 24 | -62 | 4 | 27 | -2 | 30 |
| CFO/OP | 101% | 17% | 72% | 72% | 67% | 112% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 97 | 130 | 114 | 150 | 166 | 86 |
| Inventory Days | 66 | 71 | 115 | 131 | 199 | 429 |
| Days Payable | 73 | 65 | 86 | 99 | 110 | 139 |
| Cash Conversion Cycle | 90 | 136 | 143 | 182 | 255 | 376 |
| Working Capital Days | 15 | 37 | 57 | 125 | 140 | 240 |
| ROCE % | 37% | 35% | 39% | 29% | 21% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Total Annual Installed Capacity Metric Tons (MT) |
|
||||
| Consolidated Capacity Utilization % |
|||||
| Net Working Capital Days Days |
|||||
| Sales Volume - Pharma, Food & Nutrition Metric Tons (MT) |
|||||
| Sales Volume - Specialty Ingredients Metric Tons (MT) |
|||||
| Total Actual Production Volume Metric Tons (MT) |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
28 May - Sudeep Pharma issued Q4/FY26 earnings call transcript, highlighting 27.9% revenue growth to ₹642.3 crore and FY27 plans.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Submitted annual secretarial compliance report for FY2025-26; three trading-window violations drew a warning.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
22 May - Audio recording of 22 May 2026 earnings call uploaded online; transcript to follow.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 22 May
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Dec 2025Transcript PPT
Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.